Regulatory Inflation Of Drug Prices—The Case Of Insulin

As I have explained in a previous post, Insulin is classified by the Food and Drug Administration as a biological compound. Unlike pharmaceuticals, biological compounds can have their patents extended through the modification of their product components. This creates an incentive for insulin providers to continue to modify their products instead of competing to provide cheaper options to patients.